Rockwell Medical inc   (RMTI)
Other Ticker:  
Price: $1.4500 $-0.03 -2.027%
Day's High: $1.5001 Week Perf: -4.92 %
Day's Low: $ 1.45 30 Day Perf: 4.32 %
Volume (M): 82 52 Wk High: $ 6.24
Volume (M$): $ 118 52 Wk Avg: $2.34
Open: $1.48 52 Wk Low: $1.16

 Market Capitalization (Millions $) 40
 Shares Outstanding (Millions) 28
 Employees -
 Revenues (TTM) (Millions $) 80
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 12

Rockwell Medical Inc
Rockwell Medical Inc. is a pharmaceutical company that specializes in the development, manufacturing, and commercialization of medicines and medical devices for the treatment of chronic kidney disease (CKD). The company's primary focus is on providing innovative solutions to patients with kidney disorders, striving to improve their quality of life. Rockwell Medical's products include dialysis concentrates, iron replacement therapies, and hemodialysis systems. The company is committed to advancing the standard of care for CKD patients through its research and development efforts.

   Company Address: 30142 S. Wixom Road Wixom 48393 MI
   Company Phone Number: 960-9009   Stock Exchange / Ticker: NASDAQ RMTI


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Rockwell Medical Inc

Rockwell Medical Inc Surges Ahead with Impressive Financial Results in Q3 2023

Rockwell Medical Inc, a company operating in the Major Pharmaceutical Preparations sector, has shown impressive financial results for the span ending September 30, 2023. The company managed to decrease its loss per share from $-0.40 to $-0.07 compared to the same period last year. Additionally, its income per share improved from $-0.18 to an even better figure.
The most notable achievement for Rockwell Medical Inc was its revenue growth. The company witnessed a significant jump in revenue, with a 30.517% increase to $23.20 million compared to $17.78 million in the previous year's reporting period. Furthermore, sequentially, the revenue improved by 28.664% from $18.03 million.

Rockwell Medical Inc

Rockwell Medical Inc Narrowed Losses and Shows Promising Financial Performance in Q2 2023

As an investor and financial analyst, it is always crucial to keep a close eye on the performance of various companies in the market. Today, we will be discussing the recent financial results of Rockwell Medical Inc and analyzing its impact on their shares.
In the second quarter of 2023, Rockwell Medical Inc faced a loss of $-0.18 per share, compared to $-0.56 in the same period a year ago. This indicates a significant improvement in their financial performance, as they have managed to narrow their loss per share. Furthermore, the company's shortfall increased from $-0.10 per share in the preceding financial reporting period.

Rockwell Medical Inc

Rockwell Medical Inc's Marvelous Top-line Surge in Q1 2023 Signals Promising Earnings Season Growth

Rockwell Medical Inc is a pharmaceutical company that specializes in the development and commercialization of innovative therapeutic solutions for the treatment of chronic kidney disease (CKD) and iron deficiency anemia (IDA). The company was founded in 1995 and is headquartered in Wixom, Michigan.
Recently, the company announced a surge in revenue by 28.272% to $19.67 million from the similar financial reporting period a year ago. Despite the increase in revenue, the company has lost money at $-0.10 per share. However, sequentially EPS has improved from $-0.22 per share and revenue advanced by 1.126% from $19.45 million. This improvement has been attributed to the hard work and dedication of the company workforce, who have successfully handled obstacles and caught up with customer demand while keeping net profitability in check.
In the financial span closing on March 31, 2023, Rockwell Medical Inc reported a net shortfall of $-1.750 million, instead of a deficit of $-8.941 million in the similar financial reporting period a year ago. This is a big step forward for the company and speaks to the effectiveness of their business strategy.
Rockwell Medical Inc specializes in products that provide targeted treatments for patients with renal diseases and iron deficiencies. Their lead product, Triferic, is a first-in-class iron therapy that selectively delivers iron to the bone marrow, where it is incorporated into red blood cells. This therapy is aimed at reducing the need for intravenous iron and erythropoiesis-stimulating agents (ESAs), which can increase the risk of cardiovascular events in CKD patients.
Triferic has been a key driver of growth for Rockwell Medical. The product has been approved by the FDA for use in hemodialysis patients in the U.S. and has received marketing authorization in the EU. It has been well-received by healthcare professionals and patients alike, and the company has been able to steadily expand its customer base.
Rockwell Medical Inc has a strong pipeline of product candidates in development. The company is focused on developing products that help improve the lives of CKD patients. One such candidate is Calcitriol, which is in Phase III clinical trials. This therapy is aimed at treating secondary hyperparathyroidism (SHPT) in CKD patients, a common complication that can cause bone disease, cardiovascular complications, and other complications.


Rockwell Medical Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Š 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com